Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

As global markets navigate a muted response to new U.S. tariffs and mixed economic signals, the Asian tech sector remains a focal point for investors seeking high growth opportunities. With market ...

Stocks like Wipro, Axis Bank, LTIMindtree, Indian Hotels, Lupin, Tracxn Technologies, Capital Small Finance Bank, Veranda ...

The U.S. stock market has been navigating a wave of uncertainty, with recent tariff threats from President Trump causing fluctuations across major indices such as the Dow Jones, S&P 500, and Nasdaq.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...

Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.

Their first product, Illuccix, is a diagnostic imaging agent that allows PET scanners to light up the prostate cancer cells ...

Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.

Key Takeaways BSE Sensex closed at 82,508.89, down 681.39 points (0.82%), while the Nifty 50 settled at 25,155.70, down 199.55 points (0.79%) on July 11, 2025.

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.